Journals / MN Kardiyoloji / 2000 / Cilt: 7 - Sayı: 3

Relationship between serum sex hormones, risk factors and coronary artery disease in postmenopausal women

Postmenopozal kadınlarda koroner arter hastalığı, risk faktörleri ve serum endojen seks steroidleri arasındaki ilişki

Pages
230–233
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION: These results appear that no significant difference were any sex hormones between CAD and control group in postmenopausal women.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: The difference between coronary artery disease (CAD) in premenopausal women and men suggest that endogenous sex hormones such as estrogen, progesterone and androgens have a major impact on atherosclerotic processes.
📊
Key Findings & Data:MATERIAL AND METHODS: Serum estradiol, total testosterone, free testosterone, dehydroepiandrosterone sulfate (DHEAS), sex hormone-binding globulin (SHBG), insulin, total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL-C), high density lipoprotein (HDL-C), apolipoprotein Al (apoA) and apolipoprotein B (apoB) levels were measured in 61 postmenopausal women undergoing coronary angiography (mean age 58.39±5.81 year; mean time after menopause 9.20±4.92 year).
💡
Conclusion & Impact:CONCLUSION: These results appear that no significant difference were any sex hormones between CAD and control group in postmenopausal women.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Steroidler · Koroner hastalık · Risk faktörleri

Abstract

AIM: The difference between coronary artery disease (CAD) in premenopausal women and men suggest that endogenous sex hormones such as estrogen, progesterone and androgens have a major impact on atherosclerotic processes. Estrogen is of primary importance in CAD protection both premenopausally and when replaced postmenopausally. This study was performed with the aim to determine wheather any sex hormone abnormality might be a factor in the development of CAD in postmenopausal women. MATERIAL AND METHODS: Serum estradiol, total testosterone, free testosterone, dehydroepiandrosterone sulfate (DHEAS), sex hormone-binding globulin (SHBG), insulin, total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL-C), high density lipoprotein (HDL-C), apolipoprotein Al (apoA) and apolipoprotein B (apoB) levels were measured in 61 postmenopausal women undergoing coronary angiography (mean age 58.39±5.81 year; mean time after menopause 9.20±4.92 year). Twentyeight cases whose coronary angiography were completely normal were taken as a control group (mean age 57.07±6.67 year, mean time after menopause 8.71 ±5.30 year) and 33 cases who had at least 50% obstruction or more than were taken as CAD group (mean age 59.58±4.69 year, mean time after menopause 9.65±3.88year). RESULTS: There were no significant difference measured any hormone levels between control group and CAD group (p>0.05). Serum apo A and HDL-C levels were significantly lower in CAD group than control group (respectively p<0.05, p<0.005) and apoB, diabetes mellitus were significantly higher in CAD group than control group (p<0.05). In a stepwise multiple regression analysis with the CAD as a dependent variable, only HDL-C level were significantly related to the CAD (p<0.005), and no hormone had , independent impact (p>0.05). In the multiple regression analysis with the serum lipid levels as a dependent variable and hormone ' levels as a independent variables in the model, only free testosterone were significantly related to TC (p<0.01), and LDL-C (p<0.05). CONCLUSION: These results appear that no significant difference were any sex hormones between CAD and control group in postmenopausal women.

Özet

AMAÇ: Premenopozal dönemde kadınlarda aynı yaştaki erkeklere nazaran daha az koroner arter hastalığı (KAH) görülmesi endojen seks hormonlarının ateroskleroz gelişiminde rolü olabileceğini düşündürmüştür. Kadınlarda premenopozal dönemde östrojenin kardiyovasküler koruyucu etkileri bilinmektedir. Bu çalışma postmenopozal dönemdeki kadınlarda endojen seks hormonlarının KAH ile ilişkisini araştırmak amacı ile yapıldı. GEREÇ VE YÖNTEM: Çalışmaya postmenopozal dönemde koroner anjiyografi yapılan 61 olgu (yaş ortalaması 58.39±5.81yıl, ortalama menopoz sonrası süre 9.20±4.92 yıl) alındı. Koroner anjiyografisi tamamen normal olan 28 olgu (yaş ortalaması 57.07±6.67 yıl, ortalama menopoz sonrası süre 8.71 ± 5.30 yıl) kontrol grubu, koroner anjiyografisinde en az bir koroner arterinde %50 veya daha fazla darlık saptanan 33 olgu (yaş ortalaması 59.58±4.69 yıl, ortalama menopoz sonrası süre 9.65 ± 4.59) KAH grubu olarak alındı.Tüm olgularda östradiol, total testosteron, serbest testosteron,seks hormon bağlayıcı globulin (SHBG). dehidroepiandrosteron sülfat (DHEAS), insulin, total kolesterol (TK), trigliserid (TG), düşük dansiteli lipoprotein (LDL-K), yüksek dansiteli lipoprotein (HDL-K), apolipoprotein A (apo A), apolipoprotein B (apo B) düzeyleri ölçüldü. BULGULAR: KAH grubunda kontrol grubuna göre diabetes mellitus (p<0.05), apo B (p<0.05) daha fazla iken; apo A (p<0.05) ve HDL-K düzeyi anlamlı derecede düşüktü (p<0.005). Serum östradiol, total testosteron, serbest testosteron, SHBG, DHEAS, insulin, TK,TG,LDL-K düzeyleri açısından her iki grup arasında anlamlı fark yoktu. KAH'nın bağımlı değişken olarak alındığı regresyon analizinde sadece düşük HDL-K düzeyi KAH'nın bağımsız belirleyicisi olarak saptandı (p<0.005). Endojen hormonların serum lipid düzeylerine etkisinin araştırıldığı regresyon analizinde serum serbest testosteron düzeyi TK ve LDL-K'ün bağımsız belirleyicisi olarak saplandı (sırası ile p<0.01,p<0.05). SONUÇ: Postmenopozal dönemde KAH grubu ile kontrol grubu arasında seks hormonlarının anlamlı derecede farklı olmadığı, düşük HDL-K düzeylerinin KAH gelişiminde önemli olduğu kararına varıldı.

🔖

Cite This Article

EROL, M. K., KELEŞ, M. S., BOZKURT, E., SEVİMLİ, S., KARAKELLEOĞLU, Ş., ŞENOCAK, H. (2000). Relationship between serum sex hormones, risk factors and coronary artery disease in postmenopausal women. MN Kardiyoloji, Cilt: 7 - Sayı: 3, 230–233. https://ajindex.com/articles/299198

References (15)

  1. Douglas FS. Coronary Artery Disease in Women. In: Braunwald E. eds. Heart Disease:A texbook of cardiovascular medicine. Philadelphia: W.B.Saunders 1997:1704. Folsom AR, McGovern PG, Nabulsi AA, et al.Changes in plasma lipids and lipoproteins associated with starting or stopping postmenopausal hormone replacement therapy. Am Heart J 1996
  2. 132(5):952. Sullivian JM, Fowlkes LP. Changing the natural history of coronary artery disease: Estrogens,menopause, and coronary artery disease. Cardiology Clinics 1996:14(1)
  3. Tremollieres FA, Pouilles JM, Cauneille C, Ribot C. Coronary heart disease risk factors and menoupause: a studty in 1684 French women: Atherosclerosis 1999
  4. 142(2):415. Stampfer MJ.Colditz GA.Willett WC. Menopause and heart disease.A review. Ann N Y Acad Sci 1990
  5. Stevenson JC, Crook D, Godsland IF.Influence of age and menopause on serum lipids and lipoproteins irf healthy women.Atherosclerosis 1993
  6. 98(1):83. Bonithon-Kopp C, Scarabin PY, dame B, Malmejac A, Guize L. Menopause-related changes in lipoproteins and some other cardiovascular risk factors.Int J Epidemiol 1990
  7. 19(1):42. Dallongeville J, Marecaux N, Isores D, Zylbergberg G, Fruchart JC, Amouyel P. Multiple coronary heart disease risk factors are associated with menopause and influenced by substitutive hormonal therapy in a cohort of French women. Atherosclerosis 1995
  8. 118(1):123. Bruckert E, Turpin G. Estrogens and progestins in postmenopausal women: influence on lipid parameters and cardiovascular risk. Horm res 1995
  9. Hulley S.Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease on postmenopausal women. JAMA 1998
  10. Sullivan JM, Vander ZR, Hughes JP.et al.Estrogen replacement and coronary artery disease:Effect on survival in postmonopausal women. Arch Intern Med 1990
  11. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: A quantitative assesment of the epidemiologic evidence. Prev Med 1991
  12. Skafar DF, Xu R, Morales J, Ram J, Sowers JR. Female sex hormones and cardiovascular disease in women. J Clin Endocrinol Metab 1997
  13. 82(12):3913. Peterson LR. Estrogen replacement therapy and coronary artery disease. Curr Opinion Cardiol 1998
  14. 13(4):223. Herrington DM, Gordon GB, Achuff SC, et al. Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography. J Am Coll Cardiol 1990
  15. 16(6):862. Mitchell LE, Sprecher DL,